Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
CalciMedica, Inc. (CALC) common stock is reported as beneficially owned by StemPoint Capital LP, StemPoint Capital Management GP LLC and Michelle Ross; each reporting person may be deemed to beneficially own 730,223 shares, or 9.99%. The reported amount comprises 248,972 common shares, 248,972 shares underlying Series A Warrants and 232,279 shares underlying Series B Warrants. The warrants are subject to a 9.99% beneficial ownership limitation.
The percentage calculation uses 6,828,292 common shares issued and outstanding as of August 5, 2026, adjusted for the 1-for-5 reverse stock split effective August 27, 2026, and adds the Series A and Series B warrant shares included in the reported amount. The cover-page percentages are rounded down to 9.9%.
Key Figures
Beneficially owned shares:730,223 sharesCommon shares:248,972 sharesSeries A Warrant shares:248,972 shares+4 more
7 metrics
Beneficially owned shares730,223 sharesEach reporting person may be deemed to beneficially own this amount.
Common shares248,972 sharesIncluded in the reported beneficial ownership amount.
Series A Warrant shares248,972 sharesShares underlying warrants included in the reported beneficial ownership amount.
Series B Warrant shares232,279 sharesShares underlying warrants included in the reported beneficial ownership amount.
Beneficial ownership percentage9.99%Each reporting person may be deemed to beneficially own this percentage.
Common shares issued and outstanding6,828,292 sharesAs of August 5, 2026; adjusted for the 1-for-5 reverse stock split effective August 27, 2026.
Excluded Series B Warrant shares16,693 sharesExcluded from the beneficial ownership calculation; subject to the Beneficial Ownership Limitation.
Key Terms
Beneficial Ownership Limitation, Series A Warrants, Series B Warrants
3 terms
Beneficial Ownership Limitationfinancial
"subject to a beneficial ownership limitation of 9.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Series A Warrantsfinancial
"shares of Common Stock underlying Series A Warrants"
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
Series B Warrantsfinancial
"shares of Common Stock underlying Series B Warrants"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many CALC shares do the reporting persons beneficially own?
Each reporting person may be deemed to beneficially own 730,223 shares of CALC common stock, representing 9.99%. The reported amount comprises 248,972 common shares, 248,972 shares underlying Series A Warrants and 232,279 shares underlying Series B Warrants.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CalciMedica, Inc.
(Name of Issuer)
Common stock, par value $0.00001 per share
(Title of Class of Securities)
38942Q301
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
38942Q301
1
Names of Reporting Persons
StemPoint Capital LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,223.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,223.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
38942Q301
1
Names of Reporting Persons
StemPoint Capital Management GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,223.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,223.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: StemPoint Capital Management GP LLC is a limited liability company.
SCHEDULE 13G
CUSIP Number(s):
38942Q301
1
Names of Reporting Persons
Michelle Ross
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,223.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,223.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CalciMedica, Inc.
(b)
Address of issuer's principal executive offices:
505 Coast Boulevard South, Suite 300-9, La Jolla, CA 92037
Item 2.
(a)
Name of person filing:
This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person").
(b)
Address or principal business office or, if none, residence:
The business addresses of each Reporting Person is:
520 Madison Avenue, 19th Floor
New York, NY 10022
(c)
Citizenship:
StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware.
StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware.
Michelle Ross is a citizen of the United States of America.
(d)
Title of class of securities:
Common stock, par value $0.00001 per share
(e)
CUSIP Number(s):
38942Q301
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 730,223 shares of Common stock, par value $0.00001 per share (the "Common Stock"), consisting of 248,972 shares of Common Stock and (ii) 248,972 shares of Common Stock underlying Series A Warrants, and (iii) 232,279 shares of Common Stock underlying Series B Warrants. The Series A and B Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation").
(b)
Percent of class:
Each Reporting Person may be deemed to beneficially own 9.99% shares of Common Stock, which is calculated based on (i) 6,828,292 shares of Common Stock reported as issued and outstanding as of August 5, 2026, in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026, with share amounts adjusted to give effect to a 1-for-5 reverse stock split of the Issuer's Common Stock, which became effective on August 27, 2026, plus 248,972 shares of Common Stock which may be acquired upon the exercise of Series A warrants and 232,279 shares of Common Stock which may be acquired upon the exercise of Series B warrants, which are subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act. The foregoing excludes 16,693 shares of Common Stock underlying the Series B Warrants, which is subject to the Beneficial Ownership Limitation. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
-0-
(ii) Shared power to vote or to direct the vote:
730,223. Comment: Shared voting power includes 481,251 Warrants beneficially owned by the Reporting Persons.
(iii) Sole power to dispose or to direct the disposition of:
-0-
(iv) Shared power to dispose or to direct the disposition of:
730,223. Comment: Shared dispositive power includes 481,251 Warrants beneficially owned by the Reporting Persons.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.